Tumor mutational burden from evaluation of TruSight™ Oncology 500

2019年4月29日

Watch this video to hear about TruSight™ Oncology 500 (TSO500), our solution to enable comprehensive genomic profiling. Get pan-cancer coverage targeting 523 genes from this comprehensive next-generation sequencing (NGS) assay that measures both tumor mutational burden (TMB) and microsatellite instability (MSI) from the same FFPE tumor sample. Recorded at ESMO Immuno-Oncology Congress satellite symposium with the following expert speaker panel: Speakers: • Solange Peters (CHUV, Lausanne, Switzerland) • Andrew Beggs (University of Birmingham, United Kingdom) • Fabrice Magnino (Illumina, EMEA) To get further details on enabling comprehensive genomic profiling, visit our website: https://emea.illumina.com/destination/trusight-oncology-500.html For Research Use Only. Not for use in diagnostic procedures. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

この記事を共有します